ResMed price to free cash flow RMD

Market value divided by free cash flow over the last twelve months, since 2011.

Today, Oct 23, 2026: 22.1×
10-year median: 36.0×
Against its 10-year history: 13th; percentile: 0 is its lowest day, 100 its highest
10-year range: 15.6× to 162×
Peer median: 19.8×

ResMed's price to free cash flow is 22.1× as of Oct 23, 2026.

That is below its ten-year median of 36.0×, lower than on 87% of days in the last ten years.

Over that time it ranged from 15.6× in Jun 2026 to 162× in Aug 2022.

The median for 10 medical instruments and supplies stocks of a similar size is 19.8×.

Price to free cash flow over time

median 36×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	22.1×	15.6×	22.1×
2025	20.2×	20.2×	27.2×
2024	25.3×	24.4×	31.4×
2023	31.1×	24.3×	142×
2022	93.8×	68.0×	162×
2021	92.5×	34.2×	93.3×
2020	44.1×	34.3×	59.6×
2019	45.4×	33.7×	51.6×
2018	40.0×	29.8×	40.3×
2017	33.6×	19.2×	34.2×
2016	19.2×	17.8×	22.5×
2015	20.8×	20.8×	31.6×
2014	25.7×	17.9×	25.7×
2013	19.1×	18.8×	23.5×
2012	18.1×	14.1×	20.0×
2011	16.9×	16.5×	21.8×

Against its peers

Companies in Medical - Instruments & Supplies nearest ResMed's size, closest first, today.

Company	Price to free cash flow
RMDResMed	22.1×
MDLNMedline	n/m
WSTWest Pharmaceutical Services	63.2×
BDXBecton, Dickinson and	19.8×
SOLVSolventum	n/m
PENPenumbra	59.2×
COOCooper Companies	17.2×
ALGNAlign Technology	17.3×
GMEDGlobus Medical	14.5×
PODDInsulet	35.2×
ISRGIntuitive Surgical	n/m
Peer median	19.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on ResMed

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.